Author:
Huang Rui,Zhu Li,Xue Leyang,Yan Xuebing,Wang Jian,Huang Songping,Zhang Biao,Xu Tianmin,Ji Fang,Li Chunyang,Ming Fang,Zhao Yun,Li Yang,Cheng Juan,Wang Yinling,Shao Huaping,Hong Shuqin,Chen Kang,Zhao Xiang-an,Sang Dawen,Zou Lei,Zhao Haiyan,Guan Xinying,Chen Xiaobing,Xu Biyun,Xia Juan,Chen Yuxin,Yan Xiaomin,Wei Jie,Liu Jiacheng,Liu Longgen,Zhu Chuanwu,Wu Chao
Abstract
Abstract
Background
The clinical and virological course of patients with coronavirus disease 2019 (COVID-19) are lacking. We aimed to describe the clinical and virological characteristics of COVID-19 patients from 10 designated hospitals in 10 cities of Jiangsu province, China. The factors associated with the clearance of SARS-CoV-2 were investigated.
Methods
A total of 328 hospitalized patients with COVID-19 were retrospectively recruited. The epidemiological, clinical, laboratory, radiology and treatment data were collected. The associated factors of SARS-CoV-2 clearance were analyzed.
Results
The median duration of hospitalization was 16.0 days (interquartile range [IQR] 13.0–21.0 days). On multivariate Cox regression analysis, age > 60 years (hazard ratio [HR] 0.643, 95% confidence interval [CI] 0.454–0.911, P = 0.013) was associated with the delayed SARS-CoV-2 clearance, while the atomized inhalation of interferon α-2b could improve the clearance of SARS-CoV-2 (HR, 1.357, 95% CI 1.050–1.755, P = 0.020). Twenty-six (7.9%) patients developed respiratory failure and 4 (1.2%) patients developed ARDS. Twenty (6.1%) patients were admitted to the ICU, while no patient was deceased.
Conclusions
Our study found that age > 60 years was associated with the delayed SARS-CoV-2 clearance, while treated with atomized inhalation of interferon α-2b could promote the clearance of SARS-CoV-2.
Funder
The Fundamental Research Funds for the Central Universities
Yangzhou Key R&D Program
China Postdoctoral Science Foundation for COVID-19
Publisher
Springer Science and Business Media LLC
Subject
Infectious Diseases,Virology